Neon Therapeutics' Personalized Vaccine Approach Progresses With Combination Immunotherapy Trial

NEW YORK (GenomeWeb) – Cambridge, Massachusetts-based Neon Therapeutics is continuing to make progress in its quest to use predicted neoantigen profiles in tumor samples for developing cancer vaccines and adoptive T cell therapies that can be used alone or in combination with immune checkpoint inhibitors to beat back cancer or prevent its recurrence.

The firm is interested in “exploring the therapeutic potential of targeting neoantigens, not only in vaccinations but also T cell-based strategies,” explained Neon Therapeutics Co-founder Catherine Wu, a medical oncology, cancer immunology, and virology researcher affiliated with the Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School.

In general, that is accomplished using a pipeline for sequencing tumor and matched normal exomes, detecting somatic mutations, and using that information to predict the neoantigens that are expected to prompt the most robust immune response so that they can either be incorporated into that individual’s personalized cancer vaccine or used to inform the type of T cells that are generated and expanded for the patient.

The company launched in 2015 after securing venture capital funding with the goal of bringing its proposed treatments to as many eligible patients as possible.

“We all saw great value here, great

Be the first to comment

Leave a Reply

Your email address will not be published.